Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor

Annals of Hematology

Volumn 88, Issue 1, 2009, Pages 59-66

  Vela Ojeda, J ^a,d,e   Garcia Ruiz Esparza M A ^a   Padilla Gonzalez Y ^a   Sanchez Cortes E ^a   Garcia Chavez J ^a   Montiel Cervantes, L ^a,e   Reyes Maldonado, E ^e   Majluf Cruz, A ^b   Mayani, H ^c  

^a Hospital Especialidades C M La Raza   (Mexico)

^b Hospital General Regional Gabriel Mancera   (Mexico)

^c HOSPITAL DE ONCOLOGÍA   (Mexico)

^d Instituto Politécnico Nacional ^*  (Mexico)

^e INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Amyloidosis; Multiple myeloma; Prognostic factors

Indexed keywords

ALBUMIN; CALCIUM; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; ALBUMIN BLOOD LEVEL; AMYLOIDOSIS; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOMA; NEEDLE BIOPSY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STAINING; SYMPTOMATOLOGY;

ADIPOSE TISSUE; ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; BIOPSY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; REMISSION INDUCTION; RISK FACTORS;

EID: 57049110900     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0554-0     Document Type: Article

References (24)

1. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA et al (2003) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101:3801-3808 doi: 10.1182/blood-2002-09-2707
2. Bahlis NJ, Lazarus HM (2006) Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant 38:7-15 doi: 10.1038/sj.bmt.1705395
3. Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D et al (1997) Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 27:315-319
4. Fielder K, Durie BGM (1986) Primary amyloidosis associated with multiple myeloma. Predictors of successful therapy. Am J Med 80(3):413-418 doi: 10.1016/0002-9343(86)90715-1
5. Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine 70:246-256 doi: 10.1097/ 00005792-199107000-00002
6. Gertz MA, Kyle RA (1994) Amyloidosis: Prognosis and treatment. Semin Arthritis Rheum 24:124-138 doi: 10.1016/S0049-0172(05)80006-X
7. Kyle RA, Bayrd ED (1975) Amyloidosis: A review of 236 cases. Medicine 54:271-299 doi: 10.1097/00005792-197507000-00001
8. Kyle RA (1983) Greipp, P.R. Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc 58:665-683
9. Kyle RA (1992) Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 6:347-358
10. Kyle RA (1995) Prognostic factors in multiple myeloma. Stem Cells 13:56-63
11. Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32:45-59
12. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al (1999) Long-term survival (10 years or more) in 30 patients with AL amyloidosis. Blood 93:1062-1066
13. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 28(351):1860-1873 doi: 10.1056/NEJMra041875
14. Lachmann HJ, Gallimore JR, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB et al (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating immunoglobulin free light chains following chemotherapy. Br J Haematol 122:78-84 doi: 10.1046/ j.1365-2141.2003.04433.x
15. Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN (1998) The liver in systemic amyloidosis: Insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 42:727-734
16. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L et al (2007) Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110(2):787-788 doi: 10.1182/blood-2007-02-076034
17. Palladini G, Perfetti V, Merlini G (2006) Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 136:715-720
18. Puchtler H, Sweat F (1965) Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 13(8):693-694
19. Rajkumar SV, Gertz MA, Kyle RA (1998) Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 104:232-237 doi: 10.1016/S0002-9343(98)00037-0
20. San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F et al (1995) A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448-455
21. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al (2004) High-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 140:85-93
22. The UK Myeloma Forum AL Amyloidosis Guidelines Working Group (2004) Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 125:681-700 doi: 10.1111/j.1365-2141.2004.04970.x
23. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al (1995) Poor prognosis in multiple myeloma is associated with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256
24. Westermark P, Stenkvist B (1973) A new method for the diagnosis of systemic amyloidosis. Arch Intern Med 132:522-523 doi: 10.1001/ archinte.132.4.522